BlockFi Settles With FTX, Alameda Estates for $874.5M

CoinDeskPolicyPublicado em 2024-03-05Última atualização em 2024-03-06

Resumo

The settlement with FTX and Alameda Research is a key part of BlockFi's bankruptcy and reorganization plan.

  • BlockFi has settled with the estates of FTX and Alameda Research for nearly $1 billion dollars.
  • The three companies had a long and complicated relationship, but this settlement brings BlockFi closer to full recovery for customers.

Bankrupt crypto lender BlockFi, which was caught in the contagion of FTX and declared bankruptcy days after the exchange's collapse, has reached an "in principle" agreement with the estates of FTX and Alameda Research for nearly $1 billion, according to a recent court filing, which could lead to full value recovery for BlockFi's customers.

Under the settlement, BlockFi will receive a total of $874.5 million in claims against FTX and Alameda Research. $250 million will be treated as a secured claim, which will prioritize payment to BlockFi after FTX plan to end bankruptcy, which was filed in December, is approved by its creditors.

In turn, FTX will drop its claims against BlockFi, allowing BlockFi's remaining claims to be paid out like other similar claims under FTX's plan according to the settlement. A judge still needs to sign off on the agreement.

Advertisement
Advertisement

FTX, Alameda, and BlockFi had a complicated and intertwined relationship. BlockFi received a $400 million line of credit from FTX, and FTX, under its legal name West Realm Shires, was one of BlockFi's largest creditors with a $275 million claim.

"This negotiated agreement represents an excellent outcome for BlockFi and its customers – one better than could have been anticipated even on the effective date of the Plan," BlockFi's bankruptcy administrators wrote in the filing. "[This Plan] ensures that money reserved for litigation with FTX is directed instead to customer distributions."

Edited by Nikhilesh De.

Leituras Relacionadas

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

On August 10, 2026, BPL (300246.SZ) resumed trading after a nearly week-long suspension and immediately fell by a 20% limit-down. This plunge was triggered by the termination of a planned controlling stake transfer, dashing earlier market speculation. In January 2026, Zhejiang Quwei Zhihe Partnership entered as a significant shareholder, sparking hopes. Investors speculated that its backer, Weigu Information—a specialized "little giant" company in high-reliability solid-state storage chips—might be seeking a backdoor listing through BPL. This "cross-industry restructuring" expectation fueled a strong rally, with BPL's stock price more than doubling in 2026 prior to the halt. However, the deal was called off on August 7, directly causing the sharp sell-off. Underlying BPL's vulnerability is its fundamentally weak business. The company, a medical device firm, is mired in losses, having reported three consecutive years of net losses totaling over 200 million yuan. Its core hemodialysis business is squeezed by government procurement price cuts, while growth in its patient monitor segment has stalled. Furthermore, BPL faces imminent debt pressure with convertible bonds worth approximately 218 million yuan due in September 2026, and its current stock price is far below the conversion price. The failed control transfer may represent a delayed release of negative news, but BPL's core challenges remain: reversing operational losses and addressing its urgent liquidity crisis.

marsbitHá 2h

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

marsbitHá 2h

Trading

Spot
活动图片